- Home
- SPPP vs ACTU Comparison
SPPP vs ACTU Comparison
Compare SPPP & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPP
- ACTU
- Stock Information
- Founded
- SPPP 2011
- ACTU 2015
- Country
- SPPP Canada
- ACTU United States
- Employees
- SPPP N/A
- ACTU N/A
- Industry
- SPPP
- ACTU
- Sector
- SPPP
- ACTU
- Exchange
- SPPP NYSE
- ACTU NYSE
- Market Cap
- SPPP 139.1M
- ACTU 153.1M
- IPO Year
- SPPP N/A
- ACTU 2024
- Fundamental
- Price
- SPPP $9.04
- ACTU $6.74
- Analyst Decision
- SPPP
- ACTU
- Analyst Count
- SPPP 0
- ACTU 0
- Target Price
- SPPP N/A
- ACTU N/A
- AVG Volume (30 Days)
- SPPP 274.1K
- ACTU 73.4K
- Earning Date
- SPPP 01-01-0001
- ACTU 11-13-2024
- Dividend Yield
- SPPP N/A
- ACTU N/A
- EPS Growth
- SPPP N/A
- ACTU N/A
- EPS
- SPPP N/A
- ACTU N/A
- Revenue
- SPPP N/A
- ACTU N/A
- Revenue This Year
- SPPP N/A
- ACTU N/A
- Revenue Next Year
- SPPP N/A
- ACTU N/A
- P/E Ratio
- SPPP N/A
- ACTU N/A
- Revenue Growth
- SPPP N/A
- ACTU N/A
- 52 Week Low
- SPPP $8.55
- ACTU $5.51
- 52 Week High
- SPPP $11.39
- ACTU $10.16
- Technical
- Relative Strength Index (RSI)
- SPPP 33.49
- ACTU N/A
- Support Level
- SPPP $9.22
- ACTU N/A
- Resistance Level
- SPPP $9.37
- ACTU N/A
- Average True Range (ATR)
- SPPP 0.13
- ACTU 0.00
- MACD
- SPPP -0.02
- ACTU 0.00
- Stochastic Oscillator
- SPPP 15.07
- ACTU 0.00
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.